Clearance by UK regulator allows trial to restart, with pivotal US trial hoped to follow suit to keep AstraZeneca and Oxford's candidate on track for a potential late 2020 readout. Plus, new results with Sinovac's vaccine in the elderly and progress with antibodies.

The company paid twice Immunomedics’ last closing stock price to access Trodelvy, approved for triple-negative breast cancer with potential in other solid tumors as monotherapy and in combinations.

Continuing parent firm Gilead’s busy deal-making year in immuno-oncology, Kite gets option rights to new targets. Boehringer teams with Israel’s BiomX in IBD research.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in August and September.